DEHP mediates drug resistance by metabolic reprogramming in colorectal cancer cells

Environ Sci Pollut Res Int. 2023 Apr;30(16):47780-47786. doi: 10.1007/s11356-022-25110-1. Epub 2023 Feb 7.

Abstract

Long-term exposure to diethylhexyl phthalate (DEHP), an endocrine-disrupting chemical (EDCs) and plasticizer widely used in consumer products, has been reported to be significantly positively correlated with increased risks of different human diseases, including various cancers, while the potential effect of DEHP on colorectal cancer progression was little studied. In the present study, we showed that DEHP could trigger the metabolic reprogramming of colorectal cancer cells, promote cell growth and decrease fluorouracil (5-FU) sensitivity. Mechanistic studies indicated that DEHP could reduce glycolysis activity and increase oxidative phosphorylation (OXPHOS) in SW620 cells. In addition, in vivo experiments showed that DEHP promoted tumorigenic progression and decreased survival time in mice. Collectively, our findings suggest that DEHP may be a potent risk factor for colorectal cancer development.

Keywords: Colorectal cancer; Diethylhexyl phthalate; Fluorouracil; Glycolysis; Metabolic reprogramming; Oxidative phosphorylation.

MeSH terms

  • Animals
  • Colorectal Neoplasms*
  • Diethylhexyl Phthalate* / toxicity
  • Humans
  • Insulin Resistance*
  • Mice
  • Plasticizers / toxicity

Substances

  • Diethylhexyl Phthalate
  • Plasticizers